Get the Stockscreener App
9.02
4.14%
-0.39
After Hours:
9.02
Karyopharm Therapeutics Inc stock is traded at $9.02, with a volume of 180.40K.
It is down -4.14% in the last 24 hours and up +42.72% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
See More
Previous Close:
$9.41
Open:
$9.61
24h Volume:
180.40K
Relative Volume:
0.19
Market Cap:
$203.41M
Revenue:
$146.07M
Net Income/Loss:
$-196.04M
P/E Ratio:
-0.5427
EPS:
-16.621
Net Cash Flow:
$-75.37M
1W Performance:
+7.38%
1M Performance:
+42.72%
6M Performance:
+72.80%
1Y Performance:
+43.86%
1-Day Range:
$9.02
$9.61
1-Week Range:
$8.1728
$9.61
52-Week Range:
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
9.02 | 212.21M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-05-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics (KPTI) price target increased by 13.33% to 13.87 - MSN
Karyopharm (NASDAQ: KPTI) registers resale of 8.843M shares from private placement - Stock Titan
Karyopharm Therapeutics: Selling stockholder may resell up to 8,843,036 shares of Karyopharm common stockSEC filing - marketscreener.com
Karyopharm Therapeutics: Selling Stockholder May Resell Up To 8,843,036 Shares Of Karyopharm Common StockSEC Filing - TradingView
Karyopharm Therapeutics may offer up to $400 million in securitiesSEC filing - marketscreener.com
Karyopharm Therapeutics (NASDAQ: KPTI) files $400M shelf, $100M ATM with Jefferies - Stock Titan
Karyopharm (KPTI) Q1 2025 Earnings Transcript - AOL.com
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
KPTI stock down on mixed phase III myelofibrosis combo study data - MSN
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Piper Sandler Reiterates Overweight Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
KPTI Upgraded by Piper Sandler -- Price Target Raised to $16.00 - GuruFocus
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $16 - Moomoo
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN
Is Karyopharm Therapeutics (KPTI) stock considered a safe play | Q4 2025: Below ExpectationsPricing Power - Cổng thông tin điện tử tỉnh Lào Cai
Karyopharm (KPTI) CMO logs pre-planned tax-related sale of 449 shares - Stock Titan
Karyopharm’s myelofibrosis trial selected for ASCO presentation By Investing.com - Investing.com Australia
Karyopharm’s myelofibrosis trial selected for ASCO presentation - Investing.com
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting - Karyopharm
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Is Karyopharm Therapeutics (KPTI) stock a smart investment today (Bullish Sentiment) 2026-04-20Risk Reward Ratio - Cổng thông tin điện tử tỉnh Lào Cai
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance - Insider Monkey
KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Karyopharm Therapeutics : Corporate Presentation - marketscreener.com
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):